Developer docs
API playgroundTry for free, no card

Search company profiles

Flagship Pioneering

Full company profile

uuid00002bx

Namestring
Flagship Pioneering
Legal namestring
Flagship Pioneering, Inc.
Company typeenum
Private
Founded yearint
2000
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, biotech company creation, life sciences investing, drug discovery platforms, biopharmaceutical incubation
Industry3 codes
PRIMARYFSANAAAC
Late-Stage Venture Capital (Series C+)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital & Life Sciences Company Creation
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

Traditional VC management fees charged on assets under management

flagshippioneering.com
2Carried Interest
TypeLicensing Royalties
Description

Performance fees from successful portfolio company exits including IPOs and acquisitions

flagshippioneering.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Pioneering Medicines
Description

Initiative focused on advancing novel medicines through strategic partnerships with pharmaceutical companies

flagshippioneering.com
+5 more records
Core offering1 text field

Flagship Pioneering is a life sciences venture capital and company creation firm that invents, funds, and builds biotech platform companies from inception through IPO or acquisition. Through its proprietary hypothesis-driven Flagship Labs process, the firm originates new ventures, provides initial capital, supplies CEO-Partner operational leadership, and connects portfolio companies with strategic pharmaceutical partners such as GSK, Pfizer, and AstraZeneca, ultimately harvesting returns via management fees, carried interest, and exits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over $70 billion in aggregate value created since inception
+3 more records
Product overview1 text field

Flagship Pioneering is a life sciences innovation company that invents and builds platform companies with the potential for multiple transformative products. Rather than a single unified product, Flagship operates an ecosystem of portfolio companies across human health and sustainability, each built around distinct technology platforms. Key portfolio companies include Moderna (mRNA therapeutics), Generate Biomedicines (AI-powered Generative Biology for protein therapeutics), Lila Sciences (AI Science Factories for autonomous experimentation), Valo Health (AI-enabled human causal biology platform), Vesalius Therapeutics (Physio-Logic platform for common diseases), Sana Biotechnology (Fusosome intracellular delivery), Harbinger Health (AI cancer detection), Etiome (Temporal Biodynamics for preemptive medicine), and Serif Biomedicines (Modified DNA therapeutics). Supporting initiatives include Pioneering Medicines (pharma partnerships), Pioneering Intelligence (AI/ML advancement), and Preemptive Health and Medicine Initiative (predictive healthcare). In agriculture, Flagship has Terion (AI digital infrastructure) and partnerships with Inari Agriculture and Indigo Agriculture (gene editing and microbiome technologies).

Product and service6 records
1Flagship Fund VIII
CategoryVenture Capital Fund
2Flagship Labs
CategoryCompany Creation Services
3Pioneering Medicines
CategoryStrategic Partnership Platform
4Pioneering Intelligence
CategoryAI/Technology Initiative
5Preemptive Health and Medicine Initiative
CategoryHealth Initiative
6Flagship Global Engagement
CategoryInternational Expansion Initiative
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Flagship and Lean Business Services signed MoU at BIO 2026 to collaborate on healthcare innovation and AI-enabled biomedical research in Saudi Arabia, combining Flagship's life sciences expertise with Lean's national health data infrastructure to advance precision medicine and support Vision 2030.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

Flagship Pioneering and AWS announced a strategic collaboration where AWS will serve as Flagship's preferred cloud provider, offering early-stage companies cloud credits, technical support, AI capabilities, and access to AWS customer network. Builds on prior successful partnerships with Moderna and Lila Sciences.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Merck partnering with Quotient Therapeutics (Flagship-founded somatic genomics company) to apply somatic genomics technology for discovering new drug targets in inflammatory bowel disease (IBD). Partnership worth up to $2.2 billion over four years.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Novo Nordisk entered research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases including obesity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Repertoire and Pioneering Medicines collaborating with Pfizer to develop T cell receptor bispecifics for metastatic prostate cancer. This marks the eighth program under Flagship's strategic partnership with Pfizer since July 2023.

6UK-Singapore Regulatory Innovation Corridor (MHRA and HSA)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-12-13
Description

Flagship Pioneering is the first industry partner in a cross-border regulatory corridor linking UK and Singapore health regulators to accelerate breakthrough health technologies. Focus areas include cancer, neurodegenerative disease, obesity, rare diseases, and advanced diagnostics.

ts2.tech
7King Abdullah International Medical Research Center (KAIMRC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Strategic partnership to conduct clinical trials of novel medicines in Saudi Arabia, leveraging KAIMRC's infrastructure. Initial focus on three Phase 1 and one Phase 2 programs from Flagship-founded companies targeting genetic diseases, with $70 million investment from Saudi investors. Supports Saudi Vision 2030.

prnewswire.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Collaboration to advance life sciences innovation in the UK, leveraging the Crick's research excellence and Flagship's biotech model to develop scientific platforms and therapeutic pipelines.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-09
Description

Strategic partnership leveraging IQVIA's advanced analytics, AI tools, and clinical trial expertise to accelerate development across Flagship's biopharma network.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-02-04
Description

Pfizer and Flagship Pioneering partnered to use AI-powered platforms for new drug development. Pfizer also has an ongoing partnership with Repertoire Immune Medicines for T cell-targeted immune medicines for prostate cancer, and Expediton Medicines partnership for prostate cancer therapies. Eight programs under Flagship-Pfizer strategic partnership since July 2023.

11Cambridge University Health Partners and Milner Therapeutics Institute
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-23
Description

Collaboration to accelerate biotech research and innovation, connecting academic research capabilities with Flagship's company-building expertise.

prnewswire.com
12Junaid Bajwa (UK Leadership)
Strategic tierCoreTypeOthersAnnounced on2024-10-23
Description

Junaid Bajwa appointed as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence to lead Flagship's UK operations and build connections with British research institutions.

finance.yahoo.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-03
Description

A*STAR and Flagship Pioneering announced a partnership to spur biotech innovation in Singapore, supporting Flagship's Asia-Pacific regional hub and providing access to Singapore's research ecosystem and talent.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-26
Description

Expanded strategic partnership with Thermo Fisher Scientific to jointly create new platform companies with first-in-class enabling technologies for life sciences. Also includes Mirai Bio partnership for genetic medicine development.

15GSK
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-07-29
Description

GSK entered a multibillion-dollar partnership with Flagship in respiratory and immunology. The deal includes up to $7 billion in potential payments for Flagship's portfolio companies and pipeline programs. Expanded in November 2025 with new agreements with ProFound Therapeutics and Quotient Therapeutics.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based healthcare-focused VC that builds biotech companies from inception using an in-house origination team, the closest direct analogue to Flagship Pioneering's Flagship Labs model. Same customer base (scientific founders, large pharma) and same business model of company creation plus multi-stage capital.

TypeDirect peer
Description

Long-tenured life sciences and technology VC that partners with founders to build breakthrough companies from early stage through commercialization. Highly comparable to Flagship in scientific depth, biotech portfolio, and multi-stage investing, with a similarly long track record of category-defining outcomes.

TypeDirect peer
Description

Biotech-focused early-stage VC that builds and funds new therapeutic companies. Comparable to Flagship in life sciences specialization, early-stage bias, and company-creation style, with a smaller AUM base.

TypeDirect peer
Description

Healthcare-focused VC that builds companies across biotech, medtech, and healthcare services. Comparable to Flagship in life sciences focus and willingness to incubate companies internally, with a broader therapeutic remit.

TypeBroad incumbent
Description

Major generalist VC with a dedicated bio/health fund investing across stages. Comparable to Flagship in deploying large amounts of capital into life sciences but with broader tech exposure and a different origination model.

TypeDirect peer
Description

Healthcare-dedicated investment firm across private equity, venture, and public markets. Comparable to Flagship in life sciences specialization, multi-stage investing, and pharma partnership orientation, though with a more traditional buyout and growth equity tilt.

TypeDirect peer
Description

Healthcare-focused investment manager with dedicated private equity and public equity funds. Comparable to Flagship in life sciences focus and crossover investing across stages.

TypeDirect peer
Description

Early-stage life sciences VC that builds and funds biotech companies from inception. Comparable to Flagship in company-creation DNA and life sciences focus, with smaller fund sizes.

TypeEmerging player
Description

Large early-stage VC with a growing biotech and healthcare practice. Comparable to Flagship in taking bold scientific bets but more technology-centric overall.

TypeEmerging player
Description

Tech-and-science VC that invests in frontier biotech, health, and life sciences companies. Comparable to Flagship in long-horizon bets on transformative science, though with a smaller dedicated life sciences portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries22 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment291 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flagship Pioneering

Venture Capital & Life Sciences Company Creationflagshippioneering.com

Flagship Pioneering firmographics

Firmographics
Name
Flagship Pioneering
Legal name
Flagship Pioneering, Inc.
Website
https://flagshippioneering.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Flagship Pioneering industry classification

Industry
Product category
Venture Capital & Life Sciences Company Creation
NAICS
Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAC
Late-Stage Venture Capital (Series C+)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Venture capital
  • Biotech company creation
  • Life sciences investing
  • Drug discovery platforms
  • Biopharmaceutical incubation

Where Flagship Pioneering is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Flagship Pioneering business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Management Fees: Traditional VC management fees charged on assets under management
  2. Carried Interest: Performance fees from successful portfolio company exits including IPOs and acquisitions

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Flagship Pioneering product offering

Product offering

Core offering

Flagship Pioneering is a life sciences venture capital and company creation firm that invents, funds, and builds biotech platform companies from inception through IPO or acquisition. Through its proprietary hypothesis-driven Flagship Labs process, the firm originates new ventures, provides initial capital, supplies CEO-Partner operational leadership, and connects portfolio companies with strategic pharmaceutical partners such as GSK, Pfizer, and AstraZeneca, ultimately harvesting returns via management fees, carried interest, and exits.

Product overview

Flagship Pioneering is a life sciences innovation company that invents and builds platform companies with the potential for multiple transformative products. Rather than a single unified product, Flagship operates an ecosystem of portfolio companies across human health and sustainability, each built around distinct technology platforms. Key portfolio companies include Moderna (mRNA therapeutics), Generate Biomedicines (AI-powered Generative Biology for protein therapeutics), Lila Sciences (AI Science Factories for autonomous experimentation), Valo Health (AI-enabled human causal biology platform), Vesalius Therapeutics (Physio-Logic platform for common diseases), Sana Biotechnology (Fusosome intracellular delivery), Harbinger Health (AI cancer detection), Etiome (Temporal Biodynamics for preemptive medicine), and Serif Biomedicines (Modified DNA therapeutics). Supporting initiatives include Pioneering Medicines (pharma partnerships), Pioneering Intelligence (AI/ML advancement), and Preemptive Health and Medicine Initiative (predictive healthcare). In agriculture, Flagship has Terion (AI digital infrastructure) and partnerships with Inari Agriculture and Indigo Agriculture (gene editing and microbiome technologies).

Differentiator

Problem solved

Functional benefit

Brands

  • Pioneering Medicines: Initiative focused on advancing novel medicines through strategic partnerships with pharmaceutical companies
  • Pioneering Intelligence
  • Preemptive Health and Medicine Initiative
  • Flagship Global Engagement
  • Flagship Labs
  • Flagship Futures

Products and services

  • Flagship Fund VIII
  • Flagship Labs
  • Pioneering Medicines
  • Pioneering Intelligence
  • Preemptive Health and Medicine Initiative
  • Flagship Global Engagement

Quantifiable outcome

  • Over $70 billion in aggregate value created since inception
  • +3 more outcomes

Companies that use Flagship Pioneering

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Flagship Pioneering technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature4 records

Flagship Pioneering partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, flagship, strategic and major.

  • Lean Business ServicescoreStrategic or Co-development Partner · 23 June 2026Flagship and Lean Business Services signed MoU at BIO 2026 to collaborate on healthcare innovation and AI-enabled biomedical research in Saudi Arabia, combining Flagship's life sciences expertise with Lean's national health data infrastructure to advance precision medicine and support Vision 2030.
  • Amazon Web Services (AWS)coreTechnology or Integration · 1 April 2026Flagship Pioneering and AWS announced a strategic collaboration where AWS will serve as Flagship's preferred cloud provider, offering early-stage companies cloud credits, technical support, AI capabilities, and access to AWS customer network. Builds on prior successful partnerships with Moderna and Lila Sciences.
  • Merck & Co. (MSD)flagshipStrategic or Co-development Partner · 31 March 2026Merck partnering with Quotient Therapeutics (Flagship-founded somatic genomics company) to apply somatic genomics technology for discovering new drug targets in inflammatory bowel disease (IBD). Partnership worth up to $2.2 billion over four years.
  • Novo NordiskcoreStrategic or Co-development Partner · 13 January 2026Novo Nordisk entered research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases including obesity.
  • Repertoire Immune MedicinescoreStrategic or Co-development Partner · 22 December 2025Repertoire and Pioneering Medicines collaborating with Pfizer to develop T cell receptor bispecifics for metastatic prostate cancer. This marks the eighth program under Flagship's strategic partnership with Pfizer since July 2023.
  • UK-Singapore Regulatory Innovation Corridor (MHRA and HSA)strategicStrategic or Co-development Partner · 13 December 2025Flagship Pioneering is the first industry partner in a cross-border regulatory corridor linking UK and Singapore health regulators to accelerate breakthrough health technologies. Focus areas include cancer, neurodegenerative disease, obesity, rare diseases, and advanced diagnostics.
  • King Abdullah International Medical Research Center (KAIMRC)coreStrategic or Co-development Partner · 19 November 2025Strategic partnership to conduct clinical trials of novel medicines in Saudi Arabia, leveraging KAIMRC's infrastructure. Initial focus on three Phase 1 and one Phase 2 programs from Flagship-founded companies targeting genetic diseases, with $70 million investment from Saudi investors. Supports Saudi Vision 2030.
  • Francis Crick InstitutemajorStrategic or Co-development Partner · 18 November 2025Collaboration to advance life sciences innovation in the UK, leveraging the Crick's research excellence and Flagship's biotech model to develop scientific platforms and therapeutic pipelines.
  • IQVIAmajorStrategic or Co-development Partner · 9 September 2025Strategic partnership leveraging IQVIA's advanced analytics, AI tools, and clinical trial expertise to accelerate development across Flagship's biopharma network.
  • PfizerflagshipStrategic or Co-development Partner · 4 February 2025Pfizer and Flagship Pioneering partnered to use AI-powered platforms for new drug development. Pfizer also has an ongoing partnership with Repertoire Immune Medicines for T cell-targeted immune medicines for prostate cancer, and Expediton Medicines partnership for prostate cancer therapies. Eight programs under Flagship-Pfizer strategic partnership since July 2023.
  • Cambridge University Health Partners and Milner Therapeutics InstitutemajorStrategic or Co-development Partner · 23 January 2025Collaboration to accelerate biotech research and innovation, connecting academic research capabilities with Flagship's company-building expertise.
  • Junaid Bajwa (UK Leadership)coreOthers · 23 October 2024Junaid Bajwa appointed as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence to lead Flagship's UK operations and build connections with British research institutions.
  • A*STAR (Agency for Science, Technology and Research)coreStrategic or Co-development Partner · 3 October 2024A*STAR and Flagship Pioneering announced a partnership to spur biotech innovation in Singapore, supporting Flagship's Asia-Pacific regional hub and providing access to Singapore's research ecosystem and talent.
  • Thermo Fisher ScientificcoreStrategic or Co-development Partner · 26 September 2024Expanded strategic partnership with Thermo Fisher Scientific to jointly create new platform companies with first-in-class enabling technologies for life sciences. Also includes Mirai Bio partnership for genetic medicine development.
  • GSKflagshipStrategic or Co-development Partner · 29 July 2024GSK entered a multibillion-dollar partnership with Flagship in respiratory and immunology. The deal includes up to $7 billion in potential payments for Flagship's portfolio companies and pipeline programs. Expanded in November 2025 with new agreements with ProFound Therapeutics and Quotient Therapeutics.

Scale indicators8 records

Recent moves11 records

Expansion highlights7 records

Flagship Pioneering competitors and assessment

Company assessment

Direct peers

  • Third Rock Ventures: Boston-based healthcare-focused VC that builds biotech companies from inception using an in-house origination team, the closest direct analogue to Flagship Pioneering's Flagship Labs model. Same customer base (scientific founders, large pharma) and same business model of company creation plus multi-stage capital.
  • ARCH Venture Partners: Long-tenured life sciences and technology VC that partners with founders to build breakthrough companies from early stage through commercialization. Highly comparable to Flagship in scientific depth, biotech portfolio, and multi-stage investing, with a similarly long track record of category-defining outcomes.
  • Atlas Venture: Biotech-focused early-stage VC that builds and funds new therapeutic companies. Comparable to Flagship in life sciences specialization, early-stage bias, and company-creation style, with a smaller AUM base.
  • Versant Ventures: Healthcare-focused VC that builds companies across biotech, medtech, and healthcare services. Comparable to Flagship in life sciences focus and willingness to incubate companies internally, with a broader therapeutic remit.
  • OrbiMed: Healthcare-dedicated investment firm across private equity, venture, and public markets. Comparable to Flagship in life sciences specialization, multi-stage investing, and pharma partnership orientation, though with a more traditional buyout and growth equity tilt.
  • RA Capital Management: Healthcare-focused investment manager with dedicated private equity and public equity funds. Comparable to Flagship in life sciences focus and crossover investing across stages.
  • 5AM Ventures: Early-stage life sciences VC that builds and funds biotech companies from inception. Comparable to Flagship in company-creation DNA and life sciences focus, with smaller fund sizes.

Broad incumbents

  • Andreessen Horowitz Bio Fund: Major generalist VC with a dedicated bio/health fund investing across stages. Comparable to Flagship in deploying large amounts of capital into life sciences but with broader tech exposure and a different origination model.

Emerging players

  • Khosla Ventures: Large early-stage VC with a growing biotech and healthcare practice. Comparable to Flagship in taking bold scientific bets but more technology-centric overall.
  • Lux Capital: Tech-and-science VC that invests in frontier biotech, health, and life sciences companies. Comparable to Flagship in long-horizon bets on transformative science, though with a smaller dedicated life sciences portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Flagship Pioneering social profiles

Digital presence

Flagship Pioneering financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flagship Pioneering leadership team

Management profile

Number of profiles

Profiles20 records

Flagship Pioneering subsidiaries and ownership

Company hierarchy

Subsidiaries22 records

Flagship Pioneering funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flagship Pioneering M&A and investment

M&A and investment

M&A2 records

Investments291 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flagship Pioneering

What does Flagship Pioneering do?

Flagship Pioneering is a life sciences venture capital and company creation firm that invents, funds, and builds biotech platform companies from inception through IPO or acquisition. Through its proprietary hypothesis-driven Flagship Labs process, the firm originates new ventures, provides initial capital, supplies CEO-Partner operational leadership, and connects portfolio companies with strategic pharmaceutical partners such as GSK, Pfizer, and AstraZeneca, ultimately harvesting returns via management fees, carried interest, and exits.

Is Flagship Pioneering a public or private company?

Flagship Pioneering is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Flagship Pioneering founded?

Flagship Pioneering was founded in 2000. It employs 501 to 1,000 people.

Where is Flagship Pioneering based?

Flagship Pioneering is headquartered in Cambridge, United States, in the North America region.

How does Flagship Pioneering make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Who are Flagship Pioneering's main competitors?

Direct peers on record are Third Rock Ventures, ARCH Venture Partners, Atlas Venture, Versant Ventures, OrbiMed, RA Capital Management and 5AM Ventures. Andreessen Horowitz Bio Fund is listed as a broad incumbent. Emerging players are Khosla Ventures and Lux Capital.

Does Flagship Pioneering have an API?

No public API is recorded for Flagship Pioneering.

What industry is Flagship Pioneering in?

Flagship Pioneering's product category is Venture Capital & Life Sciences Company Creation. Its primary akta.pro industry code is FSANAAAC, Late-Stage Venture Capital (Series C+), with a secondary code of FSANAAAM, Accelerators & Incubators (Investor-Operated). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechWhy 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London eventPanelists at Fierce Biotech's London event debated whether 2027 could be Europe's year for biotech investment, with Sofinnova Partners' Antoine Papiernik predicting it. He cited Europe's capital risk and Nasdaq dominance, while Flagship Pioneering announced a London AI-native company creation outpost.Nate모더나 키운 플래그십, 영국에 1억 파운드 투자…AI 신약개발 기업 육성 : 네이트 뉴스Flagship Pioneering, the venture capital firm that founded Moderna, is investing £100 million in the UK to establish an AI-based drug-discovery lab in London. The firm plans to raise over £500 million more, potentially expanding total investment to £600 million, and will hire about 50 people. It aims to expand its US-centric startup model abroad.YahooVenture firm Flagship bets £100 million to build AI-driven drug companies in BritainFlagship Pioneering opened its first non-US lab in London, investing £100 million to build AI-driven biotech companies. The firm plans to attract £500 million or more from partners and recruit about 50 scientist-entrepreneurs, using AI across drug development stages.MarketScreenerVenture firm Flagship bets £100 million to build AI-driven drug companies in BritainFlagship Pioneering opened its first non-US lab in the UK, investing £100 million to build AI-driven biotech companies. The firm, which has created over 130 companies, plans to recruit about 50 scientist-entrepreneurs and hopes to attract £500 million or more from partners.Channel NewsAsiaVenture firm Flagship bets £100 million to build AI-driven drug companies in BritainFlagship Pioneering opened its first non-US lab in London, investing £100 million to build AI-driven biotech companies. The firm plans to recruit about 50 scientist-entrepreneurs and hopes to attract £500 million or more from partners. It will use AI across all stages, from invention to clinical trials.The future of tradingVenture firm Flagship bets £100 million to build AI-driven drug companies in BritainFlagship Pioneering opened its first non-US lab in the UK, investing £100 million to build AI-driven biotech companies. The firm plans to attract £500 million or more from partners and recruit about 50 scientist-entrepreneurs, using AI across drug development. It expects to leverage the NHS's patient data for real-world evidence.Dealroom.coModerna creator Flagship commits £100M to new London company lab | Dealroom NewsFlagship Pioneering committed £100M to build Flagship Origination Lab in London, its first company-creation unit outside the US. The lab will recruit about 50 scientist-entrepreneurs to build AI-native biotech firms, following a model that has produced over 130 companies in 25 years. Flagship hopes to add £500M through partnerships, though that funding is not yet secured.Pharmaceutical TechnologyFlagship Pioneering expands to UK with £100m AI-native lab - Pharmaceutical TechnologyFlagship Pioneering committed £100m to a UK AI-native lab, the Flagship Origination Lab, to train 50 scientist-entrepreneurs. The firm expects to invest around £500m in British life sciences through partnerships. CEO Noubar Afeyan said the expansion reflects confidence in the UK ecosystem.Startup ResearcherFlagship Pioneering Launches London Origination LabFlagship Pioneering launched Flagship Origination Lab in London, its first dedicated company-creation unit outside the U.S., committing £100 million. The lab will conceive, test, fund, and build AI-native platform companies advancing health and science, with an initial team of about 50 scientist-entrepreneurs. It aims to attract an additional £500 million to expand U.K. company creation.Endpoints NewsFlagship launches UK lab to build AI-driven biotechs with £100M investmentFlagship Pioneering, the life science investor behind Moderna, launched a new London lab focused on building AI-native platform companies. The lab is backed by a £100 million investment.